Research-industry partnership wins Australian Government support to commercialise
precision oncology decision-support technology

Sydney, Australia: 18 February 2026

Bionyeri Pty Ltd and clinician, Dr Yagiz Aksoy, have secured close to $1 million in government and industry funding to commercialise the PanaceAI platform, a clinical decision-support system for precision oncology with a scalable architecture designed to expand into dermatology, ophthalmology, and other specialties.

Dr Aksoy was awarded $429,483 through the Australian Government’s Australia’s Economic Accelerator (AEA) Ignite program, Bionyeri will contribute $347,069 as industry partner, and  additional institutional contributions of $168,369 (cash and in-kind) will come from the University of Sydney and Centenary Institute.

The partnership brings together the complementary strengths of Dr Aksoy’s validated AI technology and clinical expertise, and Bionyeri’s commercialisation experience and strong international network, especially with Indonesia.

“This is what successful collaboration and research translation looks like,” said Professor Gilles Guillemin, CEO and co-founder of Bionyeri. “Dr Aksoy has developed fantastic AI tools, validated in peer-reviewed journals with real clinical impact that will make the prognosis and diagnosis of cancer patients faster than current clinical guidelines. Bionyeri’s role is to provide commercialisation expertise and access to global networks to get this technology to clinicians and oncologists.”

Dr Aksoy holds both a Doctor of Medicine, PhD in biomedical sciences and expertise in artificial intelligence, a rare combination that enables him to bridge clinical practice with advanced AI development. The PanaceAI platform is built on models he developed during his medical residency which have demonstrated accuracy improvements for prognosis, diagnosis and treatment compared with current clinical guidelines across more than 6,000 oncology patients.

“Bionyeri understood immediately what we are trying to do,” Dr Aksoy said. “Building great technology is only half the challenge. You need partners who know how to navigate regulatory pathways, build healthcare relationships, and open international markets. That’s exactly what Bionyeri brings.”

Dr Gayathri Sundaram, Chief Scientific Officer at Bionyeri, said the platform’s explainable AI approach addresses a critical barrier to clinical adoption.

“Clinicians won’t trust a black box,” Dr Sundaram said. “What makes PanaceAI different is transparency. It shows doctors exactly which factors drive each recommendation. That’s essential for real-world deployment in clinical care, and it’s why we committed significant resources to this partnership.”

Bionyeri’s established relationships with Indonesian healthcare providers, including Pak Eng Liang Tan at SOHO Global Health and Dr Evlina Suzanna at the RS Dharmais Cancer Hospital, create a pathway for initially deploying the platform in Indonesia and then across Southeast Asian markets.

“We see enormous potential beyond Australia,” Professor Guillemin said. “Southeast Asia has a huge unmet need for validated clinical decision support. Our networks position this partnership to deliver Australian innovation to the region.”

The 12-month project will fund platform integration, prospective clinical validation across Australian hospitals, and preparation for TGA Class IIa medical device certification.

 

About Dr Yagiz Aksoy

Dr Yagiz Aksoy is a clinician-scientist specialising in deployable clinical AI. He holds a Doctor of Medicine (University of Sydney) and PhD in biomedical sciences (Macquarie University), combining active medical practice with advanced AI/ML expertise. He is Senior Clinical Research Fellow at the Centenary Institute’s Biomedical AI Centre and founder of PanaceAI. Dr Aksoy is also a Chief Investigator on the $2.25 million NHMRC REP-AI project examining ethical governance of AI in healthcare.

About Bionyeri (www.bionyeri.com)

Bionyeri Pty Ltd is a Sydney-based life sciences commercialisation company focused on translating cutting-edge biomedical research into clinical applications for pain and cancer. Led by CEO and Co-Founder, Professor Gilles Guillemin and CSO Dr Gayathri Sundaram (Master of AI), Bionyeri partners with leading researchers and institutions to develop and commercialise innovative healthcare technologies and products, with established networks across Australia and Southeast Asia.